Suresh Ramalingam, MBBS
Enriched profileExecutive Director, Winship Cancer Institute of Emory University; Professor and Roberto C. Goizueta Distinguished Chair for Cancer Research, Department of Hematology and Medical Oncology, Emory University School of Medicine · Winship Cancer Institute of Emory University
Suresh Ramalingam is Executive Director, Winship Cancer Institute of Emory University; Professor and Roberto C. Goizueta Distinguished Chair for Cancer Research, Department of Hematology and Medical Oncology, Emory University School of Medicine at Winship Cancer Institute of Emory University. OpenAlex indexes 1,240 publications with 106,346 citations (h-index 125); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Suresh Ramalingam as a Highly Cited Researcher (Clinical Medicine, 2020-2025; Cross-Field, 2019).
Data verified 24 Aug 2026
Overview
Updated 27 Aug 2026
Suresh S. Ramalingam is Executive Director, Winship Cancer Institute of Emory University. The public record shows 1,240 publications with 106,346 citations (h-index 125), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 14 registered clinical trials, 9 NIH-funded awards (2014–2026).
- Most recent indexed publication: 2026 · JCO oncology practice
- Top research focus: Lung Cancer Treatments and Mutations
- 14 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 65 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 481.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
Sponsor: Emory University
Industry payments
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Gilead Sciences, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
61.7%Kinase inhibitor61.7%Tagrisso49%Retevmo22%Zykadia19%Tabrecta11%Part D<11 patientsSensory organs
19.7%Corticosteroid19.7%Dexamethasone100%Part D<11 patientsMetabolism & gastrointestinal
13%Serotonin-3 Receptor Antagonist13%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
9 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)
Emory University
FY2026$2,136,122P01CA257906
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.
Clinical cancer research
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer3,332 citations2016
- 03Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden3,138 citations2018
- 04Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer2,838 citations2019
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/suresh-ramalingam-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/sureshramalingammd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Suresh-S-Ramalingam-39843095
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
time.com/collections/time100-health-2025/7279582/suresh-ramalingam
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →time.com ↗ - Other
onclive.com/authors/suresh-s-ramalingam-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - X / Twitter
x.com/WinshipAtEmory/status/1920569717195985039
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.emoryhealthcare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.emory.edu ↗
- Chair
Thoracic Malignancies Committee, ECOG-ACRIN Cancer Research Group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine202020212022202320242025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
- Cross-Field2019verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- TIME100 Health 2025 - one of the world's most influential people in health
recognized for lung cancer/EGFR-mutant NSCLC research leading to FDA approval of osimertinib for Stage III disease
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →time.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lungcancerstoday.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
Secondary affiliations
appointments beyond the home institution- Assistant Dean for Cancer Research
Emory University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →whsc.emory.edu ↗ - Director
Division of Medical Oncology, Emory University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →whsc.emory.edu ↗ - Associate Vice President for Cancer
Woodruff Health Sciences Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →whsc.emory.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.